Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 26 October, 2012 and appeared in  MedicationBlood Glucose ControlPublic Health and PolicyIssue 649

Regular Glucose Monitoring Increases Medication Adherence and Reduces A1c

Blood glucose monitoring at least once a day is associated with reduced A1C levels and greater adherence to medication in type 2 diabetes patients who do not take insulin.... 
Advertisement

The preliminary study findings were based on a retrospective analysis of health insurance data and was led by Lifescan's Naunihal Virdi. The results are based on an analysis of 4.5 years of data gathered from 5,172 patients with type 2 diabetes who were newly treated with noninsulin diabetes medication. Patients who tested their blood glucose showed a greater overall decrease in A1C than those not testing (-1.4 vs. -0.6 A1C percentage points respectively). Overall, higher blood glucose testing frequency was associated with greater decreases in A1C levels. Patients who tested at least once per day had the greatest reductions in A1C levels compared with patients who tested less frequently, or not at all.

This study also found that patients who tested their blood glucose were more likely to take their diabetes medication as prescribed than patients who didn't test (49.9% vs. 38.2%, respectively). Again, testing frequency was a factor, with 64.1% of patients who tested at least once a day being adherent to their medications compared to less than 50% of those testing less frequently.

"Good glycemic control is key to reducing complications in patients with diabetes," Virdi said. "For type 2 patients who don't take insulin, this study adds to the growing body of evidence that regular self-monitoring of blood sugar may contribute to improved diabetes control, as well as improved compliance in taking medications as prescribed."

The study findings were based on a retrospective analysis of health insurance data and are considered by the authors as preliminary to other studies that may confirm these findings via a prospective clinical trial.

Diabetes Technology & Therapeutics Sept. 2012 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 26 October, 2012 and appeared in  MedicationBlood Glucose ControlPublic Health and PolicyIssue 649

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control
Search Articles On Diabetes In Control